News
Press Releases
2019/06/29
WuXi AppTec Named One of MIT Technology Review's 50 Smartest Companies
SHANGHAI, June 29, 2019 -- WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company, announces that it has been selected as one of MIT Technology Review's 50 Smartest Companies (TR50) for 2019. WuXi was chosen for its dedication in building an open-access R&D enabling platform for companies around the world to discover and develop new medicines for patients efficiently.
Read more2019/05/06
WuXi AppTec Acquires Pharmapace to Enhance Biometrics Services for Clinical Development
WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company, today announced that it has acquired Pharmapace, Inc., a US-based clinical research services company with expertise of providing high quality biometrics services for all phases of clinical trials, regulatory submissions, and post marketing support. Upon the closing of this acquisition, Pharmapace will become a wholly-owned subsidiary of WuXi Clinical - the clinical CRO arm of WuXi AppTec - and will continue to focus on growing its core biometrics competences and integrate with WuXi Clinical’s other clinical development services.
Read more2019/04/30
WuXi AppTec Announces Strong First-Quarter 2019 Results
(SHANGHAI, April 30, 2019) — WuXi AppTec Co., Ltd. (stock code: 603259.SH / 02359.HK), a leading global pharmaceutical and medical device open-access capability and technology platform company with global operations, announces its financial results for first quarter 2019.
Read more2019/04/08
WuXi AppTec Appoints Dr. Frederick H. Hausheer as Chief Medical Officer
SHANGHAI and AUSTIN, Texas, April 8, 2019 -- WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company, today announces the appointment of Dr. Frederick H. Hausheer as Chief Medical Officer for the company.
Read more2019/03/27
WuXi STA’s New Drug Product Manufacturing Facility Passes First European MPA GMP Inspection
SHANGHAI, March 27, 2019 – STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – announces that its new drug product manufacturing facility in Shanghai Pilot Free Trade Zone has passed its first GMP inspection by the European Medical Products Agency (MPA). The new facility was opened at the end of 2018, and the successful inspection demonstrates the outstanding quality control system and rapid development of WuXi STA’s drug product services.
Read more